<DOC>
	<DOCNO>NCT02716818</DOCNO>
	<brief_summary>This study parallel arm , randomise , open-label study , include dose titration admission four overnight stay 24-hour endocrine profile . It compare efficacy , safety tolerability Chronocort® standard glucocorticoid replacement therapy treatment congenital adrenal hyperplasia ( CAH ) treatment period 6 month . Dose titration decision treatment group make central independent physician , blind treatment arm , use information generate 24-hour endocrine profile . Each treatment arm subject titration rule throughout study , ensure opportunity optimisation control androgens group .</brief_summary>
	<brief_title>Comparison Chronocort® With Standard Glucocorticoid Therapy Patients With Congenital Adrenal Hyperplasia</brief_title>
	<detailed_description>At baseline , subject admit overnight 24-hour endocrine profile whilst standard therapy . Subjects attend study site morning 17-hydroxyprogesterone ( 17-OHP ) androstenedione ( A4 ) level assess 15:00 , 17:00 , 19:00 , 21:00 , 23:00 , 01:00 , 03:00 , 05:00 , 07:00 , 09:00 , 11:00 , 13:00 15:00 . Safety laboratory test , DEXA scan body composition , height , weight waist circumference record . Subjects randomise Chronocort® continue standard care . Randomisation stratify baseline treatment : 1. hydrocortisone 2. prednisone prednisolone , alone combination hydrocortisone 3. dexamethasone combination glucorticoid The initial dose set start Chronocort® treatment base hydrocortisone dose equivalent baseline therapy accordance standard clinical practice . Further dose refinement/titration conduct treatment group necessary 4 week 12 week use standardised titration algorithm subject re-admitted 24-hour endocrine profile . Safety endpoint also measure 07:00 morning sample 24-hour profile assessment day . The decision change dose treatment group make central independent blind physician , actual change dose make local investigator look subject . At 6 month , baseline test repeat ( include 24-hour profile ) . All subject may continue Chronocort® , whatever randomise treatment , part open-label extension study ( conduct separate protocol ) . Stress dose hydrocortisone give throughout study intercurrent illnesses medically indicate accord `` sick day rule '' .</detailed_description>
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Adrenal Hyperplasia , Congenital</mesh_term>
	<mesh_term>Adrenogenital Syndrome</mesh_term>
	<mesh_term>Adrenocortical Hyperfunction</mesh_term>
	<mesh_term>Glucocorticoids</mesh_term>
	<mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
	<mesh_term>Cortisol succinate</mesh_term>
	<mesh_term>Hydrocortisone acetate</mesh_term>
	<mesh_term>Hydrocortisone</mesh_term>
	<criteria>1 . Known CAH due 21hydroxylase deficiency ( classic CAH ) diagnose childhood document ( time ) elevate 17OHP and/or A4 currently treat hydrocortisone , prednisone , prednisolone dexamethasone ( combination aforementioned glucocorticoid ) stable glucocorticoid therapy minimum 6 month . 2 . Provision sign write informed consent . 3 . Nonpregnant , nonlactating female post menopausal , naturally surgically sterile , childbearing potential negative urinary pregnancy test use medically acceptable method contraception . 4 . Plasma renin activity ( PRA ) less 1.5 time upper limit normal ( ULN ) screen within 3 month prior screen , except subject diagnose hypertension renin use monitor fludrocortisone replacement . 5 . Plasma renin activity ( PRA ) less 1.5 time upper limit normal ( ULN ) screen within 3 month prior screen , except subject diagnose hypertension renin use monitor fludrocortisone replacement . 1 . Comorbid condition require daily administration medication ( consumption material ) interfere metabolism glucocorticoid . 2 . Clinical biochemical evidence hepatic renal disease . Creatinine twice ULN elevate liver function test ( ALT AST &gt; 2 time ULN ) . 3 . Subjects regular daily inhale , topical , nasal oral steroid indication CAH . 4 . Subjects significant medical psychiatric condition opinion investigator would preclude participation trial . 5 . History malignancy ( basal cell carcinoma successfully treat &gt; 6 month prior entry study ) . 6 . Participation another clinical trial investigational license drug device within 3 month prior inclusion study . 7 . Subjects history bilateral adrenalectomy . 8 . Subjects previously expose Chronocort® . 9 . Subjects unable comply requirement protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Glucocorticoid therapy</keyword>
</DOC>